Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects

FFR-rFVIIa is an antithrombotic agent, which has also proven to have antire stenotic properties in animal models. FFR-rFVIIa is a modified recombinant FVIIa in which the catalytic site is irreversibly inactivated by a syntheti c tripeptide covalently bound with the FVIIa molecule. The modified rFVIIa retains its tissue factor (TF) binding capacity but is otherwise enzymatica lly inactive. A double-blind, placebo-controlled, randomized dose escalatio n trial was conducted to investigate eight single Lv. doses of FFR-rFVIIa ( 0.01, 0.02, 0.05, 0.08, 0.12, 0.18, 0.27, or 0.40 mg/kg body weight) in hea lthy male volunteers (n = 62). Safety, pharmacokinetics, and pharmacodynami cs of FFR-rFVIIa were assessed. Mean (SD)AUC(0-infinity)rangedJrom 0.35 (0. 11) to 28.8 (3.5) mug(.)h/ml, and mean C-max ranged from 0.078 (0.019) to 4 .8 (0.7) mug/ml. The mean elimination half-life ranged from 3.8 to 5.8 hour s. Mean AUC(0-infinity)increased with increasing dose levels. C-max appeare d to be proportional to the dose level, with the exception of the lowest do se level. A dose-dependent prolongation of the prothrombin time was found, demonstrating that FFR-rFVIIa inhibited coagulation via the TF-dependent pa thway. FFR-rFVIIa was generally well tolerated at all dose levels studied. (C) 2001 the American College of Clinical Pharmacology.